ACMA Weekly
Accreditation Council for Medical Affairs (ACMA)
Life Sciences Accreditation & Certification. Medical Affairs, MSLs, Prior Auth, Biologics/Biosimilars
Key Learning
Missed our webinar? Catch up on essential insights about the role of an FRM now!
Highlight Article
New Blog: Mastering Prior Authorization Roles: Responsibilities and Training Demands Explored - Click Here to Read!
Industry News Highlight
Strategic Partnerships
Daiichi Sankyo and Merck: A $22 billion deal for the development and commercialization of three antibody-drug conjugates for oncology.
Pfizer and Flagship Pioneering: A $7.05 billion research partnership to develop novel therapies.
Voyager Therapeutics and Neurocrine Biosciences: A $4.41 billion deal to develop gene therapies for neurological conditions.
Mergers and Acquisitions
Amgen and Horizon Therapeutics: Amgen announced its acquisition of Horizon Therapeutics for $27.8 billion, enhancing its portfolio of treatments for rare diseases.
AstraZeneca and CinCor Pharma: AstraZeneca acquired CinCor Pharma in a $1.8 billion deal, aimed at accelerating its cardiovascular drug development efforts.
ACMA Summit
Save the Date! The inaugural ACMA MSL & Medical Affairs Excellence Summit is here! - Click here to learn more.
?? ACMA Webinar
Become Board Certified in Medical Affairs
Hear From BCMAS Graduates
About ACMA
The Accreditation Council for Medical Affairs (ACMA) is accredited by the International Association for Continuing Education and Training (IACET/ANSI) and is a member of the Institute for Credentialing Excellence (ICE).
Our mission is to establish standards of excellence in the life sciences.
ACMA has collaborated with over 250 pharmaceuticals companies and 25,000 individual professionals worldwide by helping them build capabilities in commercial, market access, and medical affairs support through certification and training.